Discovering small molecules to control stem cell fate

Future Medicinal Chemistry

Volumn 3, Issue 12, 2011, Pages 1539-1549

  Andrews, Paul D ^a  

^a Cellartis AB   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; PRIMER DNA;

ADIPOCYTE; CELL CYCLE; CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; CELL POPULATION; CELL RENEWAL; CELL STRAIN HEK293; CELL SURVIVAL; DRUG DEVELOPMENT; EMBRYONIC STEM CELL; EPIGENETICS; HIGH THROUGHPUT SCREENING; HUMAN; LIVER CELL; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; STRUCTURE ACTIVITY RELATION;

CELL DIFFERENTIATION; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; EMBRYONIC STEM CELLS; HUMANS; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; SMALL MOLECULE LIBRARIES; STEM CELLS;

EID: 80052430364     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.98     Document Type: Review

References (50)

1. Mckernan R, Mcneish J, Smith D. Pharma's developing interest in stem cells. Cell Stem Cell 6(6), 517-520 (2010).
2. Enver T, Pera M, Peterson C, Andrews PW. Stem cell states, fates, and the rules of attraction. Cell Stem Cell 4(5), 387-397 (2009).
3. Xu Y, Shi Y, Ding S. A chemical approach to stem-cell biology and regenerative medicine. Nature 453(7193), 338-344 (2008). (Pubitemid 351693140)
4. Andrews PD. Turn back the clock and be healed: induced pluripotent stem cells and their future impact on drug discovery and regenerative medicine. Eur. Pharm. Rev. 2, 48-52 (2010).
5. Gunaseeli I, Doss MX, Antzelevitch C, Hescheler J, Sachinidis A. Induced pluripotent stem cells as a model foraccelerated patient- and disease-specific drug discovery. Curr. Med. Chem. 17(8), 759-766 (2010).
6. Adewumi O, Aflatoonian B, Ahrlund- Richter L et al. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat. Biotechnol. 25(7), 803-816 (2007). (Pubitemid 47052190)
7. Tanasijevic B, Dai B, Ezashi T, Livingston K, Roberts RM, Rasmussen TP. Progressive accumulation of epigenetic heterogeneity during human ES cell culture. Epigenetics 4(5), 330-338 (2009).
8. Watanabe K, Ueno M, Kamiya D et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 25(6), 681-686 (2007). (Pubitemid 46897207)
9. Andrews PD, Becroft M, Aspegren A et al. High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. Biochem. J. 432(1), 21-33 (2010).
10. Barbaric I, Gokhale PJ, Jones M, Glen A, Baker D, Andrews PW. Novel regulators of stem cell fates identified by a multivariate phenotype screen of small compounds on human embryonic stem cell colonies. Stem Cell Res. 5(2), 104-119 (2010).
11. Xu Y, Zhu X, Hahm Hs et al. Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc. Natl Acad. Sci. USA 107(18), 8129-8134 (2010).
12. Claassen D, Desler M, Rizzino A. ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells. Mol. Reprod. Dev. 76(8), 722-732 (2009).
13. Nichols J, Smith A. Naive and primed pluripotent states. Cell Stem Cell 4(6), 487-492 (2009).
14. Hanna J, Cheng Aw, Saha K et al. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc. Natl Acad. Sci. USA 107(20), 9222-9227 (2010).
15. Buecker C, Chen H-H, Polo JM et al. A murine ESC-like state facilitates transgenesis and homologous recombination in human pluripotent stem cells. Cell Stem Cell 6(6), 535-546 (2010).
16. Ying Ql, Wray J, Nichols J et al. The ground state of embryonic stem cell self-renewal. Nature 453(7194), 519-523 (2008). (Pubitemid 351733324)
17. Chen S, Do JT, Zhang Q et al. Self-renewal of embryonic stem cells by a small molecule. Proc. Natl Acad. Sci. USA 103(46), 17266-17271 (2006). (Pubitemid 44788958)
18. Zhang Q, Major MB, Takanashi S et al. Small-molecule synergist of the Wnt/b-catenin signaling pathway. Proc. Natl Acad. Sci. USA 104(18), 7444-7448 (2007). (Pubitemid 47185925)
19. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3- specific inhibitor. Nat. Med. 10(1), 55-63 (2004). (Pubitemid 38524699)
20. Ding S, Wu TY, Brinker A et al. Synthetic small molecules that control stem cell fate. Proc. Natl Acad. Sci. USA 100(13), 7632-7637 (2003). (Pubitemid 36760021)
21. Miyabayashi T, Teo JL, Yamamoto M, Mcmillan M, Nguyen C, Kahn M. Wnt/b-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc. Natl Acad. Sci. USA 104(13), 5668-5673 (2007). (Pubitemid 47175738)
22. Andrews P, Frearson J. Influencing Stem Cell Fate Using Small Molecules. European Pharmaceutical Reviews 1(1), 18-27 (2008).
23. Zhu S, Wurdak H, Schultz PG. Directed embryonic stem cell differentiation with small molecules. Future Med. Chem. 2(6), 965-973 (2010).
24. Li W, Ding S. Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. Trends Pharmacol. Sci. 31(1), 36-45 (2010).
25. Yu Pb, Hong CC, Sachidanandan C et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 4(1), 33-41 (2008). (Pubitemid 350273653)
26. Hao J, Daleo MA, Murphy CK et al. Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. PLoS ONE 3(8), e2904 (2008).
27. Cuny GD, Yu PB, Laha JK et al. Structure- activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg. Med. Chem. Lett. 18(15), 4388-4392 (2008).
28. Hao J, Ho JN, Lewis Ja et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem. Biol. 5(2), 245-253 (2010).
29. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27(3), 275-280 (2009).
30. Morizane A, Doi D, Kikuchi T, Nishimura K, Takahashi J. Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. J. Neurosci. Res. (2010).
31. Zhou J, Su P, Li D, Tsang S, Duan E, Wang F. High-efficiency induction of neural conversion in human ESCs and human induced pluripotent stem cells with a single chemical inhibitor of transforming growth factor b superfamily receptors. Stem Cells 28(10), 1741-1750 (2010).
32. Zhu S, Wurdak H, Wang J et al. A small molecule primes embryonic stem cells for differentiation. Cell Stem Cell 4(5), 416-426 (2009).
33. Borowiak M, Maehr R, Chen S et al. Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell 4(4), 348-358 (2009).
34. Chen S, Borowiak M, Fox JL et al. A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat. Chem. Biol. 5(4), 258-265 (2009).
35. Nakagawa M, Yamanaka S. Reprogramming of somatic cells to pluripotency. Adv. Exp. Med. Biol. 695, 215-224 (2011).
36. Kiskinis E, Eggan K. Progress toward the clinical application of patient-specific pluripotent stem cells. J. Clin. Invest. 120(1), 51-59 (2010).
37. Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 5(6), 584-595 (2009).
38. Lin T, Ambasudhan R, Yuan X et al. A chemical platform for improved induction of human iPSCs. Nat Meth 6(11), 805-808 (2009).
39. Shi Y, Desponts C, Do JT, Hahm HS, Scholer HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 3(5), 568-574 (2008).
40. Huangfu D, Osafune K, Maehr R et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol. 26(11), 1269-1275 (2008).
41. Li W, Zhou H, Abujarour R et al. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 27(12), 2992-3000 (2009).
42. Ichida JK, Blanchard J, Lam K et al. A small-molecule inhibitor of TGF-β signaling replaces Sox2 in reprogramming by inducing nanog. Cell Stem Cell 5(5), 491-503 (2009).
43. Maherali N, Hochedlinger K. TGFb signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Curr. Biol. 19(20), 1718-1723 (2009).
44. Lyssiotis CA, Foreman RK, Staerk J et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc. Natl Acad. Sci. USA 106(22), 8912-8917 (2009).
45. Chen S, Zhang Q, Wu X, Schultz PG, Ding S. Dedifferentiation of lineage-committed cells by a small molecule. J. Am. Chem. Soc. 126(2), 410-411 (2004). (Pubitemid 38084591)
46. Anastasia L, Sampaolesi M, Papini N et al. Reversine-treated fibroblasts acquire myogenic competence in vitro and in regenerating skeletal muscle. Cell Death Differ. 13(12), 2042-2051 (2006). (Pubitemid 44742687)
47. Chen S, Takanashi S, Zhang Q et al. Reversine increases the plasticity of lineage-committed mammalian cells. Proc. Natl Acad. Sci. USA 104(25), 10482-10487 (2007). (Pubitemid 47185691)
48. Lee EK, Bae GU, You JS et al. Reversine increases the plasticity of lineage-committed cells toward neuroectodermal lineage. J. Biol. Chem. 284(5), 2891-2901 (2009).
49. D'alise AM, Amabile G, Iovino M et al. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol. Cancer Ther. 7(5), 1140-1149 (2008).
50. Amabile G, D'alise AM, Iovino M et al. The Aurora B kinase activity is required for the maintenance of the differentiated state of murine myoblasts. Cell Death Differ. 16(2), 321-330 (2009).